Skip to main content
Clinical Trials/NCT06121635
NCT06121635
Active, not recruiting
Not Applicable

The Effects of Transcranial Direct Current Stimulation and Transcutaneous Spinal Direct Current Stimulation on Robot-assisted Gait Training in Patients With Multiple Sclerosis

Istanbul Medeniyet University1 site in 1 country36 target enrollmentDecember 20, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
Istanbul Medeniyet University
Enrollment
36
Locations
1
Primary Endpoint
Timed 25-Foot Walk (T25-FW)
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

The primary aim of this study is to determine the transcranial direct current stimulation and transcutaneous spinal direct current stimulation in addition to robot-assisted walking training in individuals with Multiple sclerosis; to examine the effects on motor functions against each other and sham application. Secondary aim of this study is to show the relation of these effects with tDCS and ts-DCS through fatigue and quality of life evaluations.

Detailed Description

These study is planned to be carried out in the Cadde Medical Center clinic. The patients who will participate in the study will be determined according to the inclusion criteria among the patients who applied to the Multiple Sclerosis Outpatient Clinic of Istanbul Medeniyet University Göztepe Research Hospital, Department of Neurology. As a result of the power analysis, 36 participants were planned to be included in the study. 20 minutes of non-invasive brain stimulation will be applied to the individuals participating in these study before the 20 minutes robot-assisted walking training (RATG), 3 days a week for 4 weeks. Participants will be divided into 3 groups according to the type of stimulation applied by simple randomization. These groups are 1) anodal tDCS + sham ts-DCS; 2) sham tDCS + cathodal ts-DCS 3) sham tDCS + sham ts-DCS. The same evaluations will be applied to all participants during the study and the evaluations are planned as before and after the intervention. The data collected as a result of the evaluations will be analyzed with SPSS version 22.

Registry
clinicaltrials.gov
Start Date
December 20, 2023
End Date
July 30, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Istanbul Medeniyet University
Responsible Party
Principal Investigator
Principal Investigator

Gulser CINBAZ

research assistant

Istanbul Medeniyet University

Eligibility Criteria

Inclusion Criteria

  • Patients diagnosed with MS and suffering from walking difficulties due to MS
  • EDSS score between 2-6
  • Being over 18 years old

Exclusion Criteria

  • Relapsed within the last two months
  • Changed medication within 45 days
  • Hospitalized in the last three months
  • Had other neurological or musculoskeletal problems
  • Had an obstacle to stimulation (skin problems, metal implants, etc.)
  • Do not want to participate in the study individuals

Outcomes

Primary Outcomes

Timed 25-Foot Walk (T25-FW)

Time Frame: 4 weeks

Timed 25 Foot Walking Test was used for objective evaluation of walking. In T25-FW, which evaluates lower extremity function, the individual is asked to walk 25 steps as quickly and safely as possible (if he/she uses a walking aid, this is done together). The time spent walking is recorded in seconds.

Time Up and Go (TUG)

Time Frame: 4 weeks

It is a performance-based test used to evaluate functional mobility and walking speed. The person is asked to get up from the chair he/she is sitting on without support from his/her arms, walk 3 meters at a safe and normal speed, turn around, walk back, sit on the chair again, and the time is recorded in seconds (sec). The test is started with the patient's feet flat on the floor and arms resting on the armrest of the chair. Three repetitions are made and the best result is recorded.

Multiple Sclerosis Walking Scale-12 (MSWS-12)

Time Frame: 4 weeks

It is a 12-item rating scale used to assess individuals' perspectives on the impact of their disease on their ability to walk. During the test, patients are asked to rate how much MS affects their mobility, such as standing, walking, running, and climbing stairs, on a 5-point Likert Scale (1=almost not at all, 5=extremely). A high score indicates that walking ability is affected or the patient has difficulty walking. The lowest score can be 12 and the highest score can be 60 from the test.

Gait Speed Assessment

Time Frame: 4 weeks

Calculation of walking speed will be done by 2D video analysis method. Kinovea 2D motion analysis software (GPLv2 license, 2019) will be used for analysis. The method has validity and reliability. The videos taken with the cameras placed laterally will be uploaded to the program and the necessary calculations will be made.

Secondary Outcomes

  • Fatigue Severity Scale (FSS)(4 weeks)
  • Fatigue Impact Scale (FIS)(4 weeks)

Study Sites (1)

Loading locations...

Similar Trials